Xenetic Biosciences Files 8-K on Financials
Ticker: XBIO · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1534525
| Field | Detail |
|---|---|
| Company | Xenetic Biosciences, Inc. (XBIO) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, operations
TL;DR
Xenetic Biosciences dropped an 8-K with financial updates. Check it out.
AI Summary
Xenetic Biosciences, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition, as well as presenting financial statements and exhibits. The filing details the company's financial performance and provides supporting documentation.
Why It Matters
This filing provides investors with updated financial information and operational results for Xenetic Biosciences, Inc., crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Xenetic Biosciences, Inc. (company) — Registrant
- August 13, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Framingham, Massachusetts (location) — Principal executive offices
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included as an item of information, but the specific details of these statements are not provided in the excerpt.
What is the primary purpose of this 8-K filing for Xenetic Biosciences, Inc.?
The primary purpose is to report on the 'Results of Operations and Financial Condition' and to provide 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 13, 2025.
What is Xenetic Biosciences, Inc.'s state of incorporation and IRS Employer Identification Number?
Xenetic Biosciences, Inc. is incorporated in Nevada and its IRS Employer Identification Number is 45-2952962.
What were Xenetic Biosciences, Inc.'s former company names and when did they change?
The company was formerly known as General Sales & Leasing, Inc. (name change on 20130227) and GENERAL AIRCRAFT INC. (name change on 20111108).
Filing Stats: 830 words · 3 min read · ~3 pages · Grade level 12.5 · Accepted 2025-08-13 08:00:36
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share XBIO The Nasdaq
Filing Documents
- xenetic_8k.htm (8-K) — 29KB
- xenetic_ex9901.htm (EX-99.1) — 17KB
- image_001.gif (GRAPHIC) — 5KB
- 0001683168-25-006001.txt ( ) — 220KB
- xbio-20250813.xsd (EX-101.SCH) — 3KB
- xbio-20250813_lab.xml (EX-101.LAB) — 33KB
- xbio-20250813_pre.xml (EX-101.PRE) — 22KB
- xenetic_8k_htm.xml (XML) — 3KB
02
Item 2.02. Results of Operations and Financial Condition. On August 13, 2025, Xenetic Biosciences, Inc. (the "Company") issued a press release announcing results for the three months ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and hereby incorporated in this Item 2.02 by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
FORWARD-LOOKING STATEMENTS
FORWARD-LOOKING STATEMENTS This Form 8-K, including the press release, contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K, including the press release, other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements or results to differ materially from the activities and results anticipated in forward-looking in the Company's reports filed with the Securities and Exchange Commission ("SEC"), including the Company's annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this Form 8-K, including the press release, speak only as
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 13, 2025 pertaining to the financial results of the Company for the three months ended June 30, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENETIC BIOSCIENCES, INC. By: /s/ James Parslow Date: August 13, 2025 Name: James Parslow Title: Interim Chief Executive Officer & Chief Financial Officer 3